Astellas submits MAA to EMA for enzalutamide
The submission is based on Phase 3 AFFIRM trial of enzalutamide in post-chemotherapy prostate cancer patients in which seizure was reported in less than 1% of enzalutamide-treated patients.
ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT).
EPS is offering analytical services, such as nuclear magnetic resonance spectroscopy (NMR) and liquid chromatography-mass spectrometry (LC-MS), and microbiological testing such as comprehensive drug resistance profiling and biofilm